The Hematopoietic Stem Cell Transplantation Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Hematopoietic Stem Cell Transplantation Market:
https://www.thebusinessresearchcompany.com/report/hematopoietic-stem-cell-transplantation-global-market-report
According to The Business Research Company’s Hematopoietic Stem Cell Transplantation Global Market Report 2024, The hematopoietic stem cell transplantation market size has grown strongly in recent years. It will grow from $4.24 billion in 2023 to $4.65 billion in 2024 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to early transplantation techniques, limited indications and donor sources, advancements in conditioning regimens, emergence of allogeneic transplants, regulatory milestones.
The hematopoietic stem cell transplantation market size is expected to see rapid growth in the next few years. It will grow to $6.82 billion in 2028 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to expanded treatment indications, donor source diversification, personalized medicine and genomics, regulatory changes and guidelines, market expansion and accessibility. Major trends in the forecast period include advancements in transplant techniques, expansion of indications, emerging cellular therapies, donor diversification, precision medicine approach.
The increased frequency of blood cancer is expected to propel the growth of the hematopoietic stem cell transplantation market. A group of malignancies that impact the development and operation of blood cells are referred to as blood cancers. Leukemia, lymphoma, and myeloma are the three main types of blood cancer. By replacing stem cells and bone marrow cells that have been killed by the malignancy, hematopoietic stem cell transplantation is generally used to treat blood cancer. These new stem cells can then move to the bone marrow and start creating new blood cells. So, these factors boost the hematopoietic stem cell transplantation market. For instance, in August 2022, according to the report shared by Blood Cancer UK, a UK-based non-profit organization, there are 41,000 blood cancer cases identified each year, making blood cancer the sixth most prevalent malignancy in the UK. Blood cancer, which affects one in 16 men and one in 22 women at some time in their lives, will afflict around 250,000 people in the UK in 2022. Additionally, more than 500 children under the age of 15 are affected by blood cancer each year. 400 of them have pediatric leukemia, and 100 of them have lymphoma. Therefore, the increased frequency of blood cancer drives the hematopoietic stem cell transplantation market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=10445&type=smp
The hematopoietic stem cell transplantation market covered in this report is segmented –
1) By Type: Allogeneic, Autologous
2) By Indication: Leukemia, Lymphatic Disorder, Myeloma, Other Non-Malignant Disorders
3) By Application: Bone Marrow Transplant, Peripheral Blood Stem Cell Transplant, Cord Blood Transplant
4) By End User: Hospital Pharmacy, Retail Pharmacy, Specialty Clinics
Product approvals are a key trend gaining popularity in the hematopoietic stem cell transplantation market. Major companies operating in the hematopoietic stem cell transplantation market are adopting product approvals to sustain their position in the market. For instance, in April 2022, Priothera Ltd., an Ireland-based late-clinical stage biotechnology company, received the United States Food and Drug Administration (FDA) clearance of an investigational new drug (IND) to begin an allogeneic hematopoietic stem cell transplant (HSCT) Phase IIb/III research study with mocravimod in patients with acute myeloid leukemia (AML). Mocravimod is a synthetic sphingosine 1-phosphate receptor (S1PR) modulator, also known as KRP203. Phase I and Phase II trials have evaluated the safety, tolerability, and effectiveness of this unique experimental medication for a number of autoimmune diseases.
The hematopoietic stem cell transplantation market report table of contents includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
Major Players:
- Pluristem Therapeutics Inc.
- Lonza Group AG
- Escape Therapeutics Inc.
- Regen Biopharma Inc.
- Bluebird Bio Inc.
Related Reports:
https://goodprnews.com/drug-infusion-systems-market-size/
https://goodprnews.com/drug-coated-balloons-global-market-report/
https://topprnews.com/drug-infusion-systems-global-market-report/
https://topprnews.com/drug-coated-balloon-catheter-market-size-study/
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
